Regulatory T Cells in Arterivirus and Coronavirus Infections: Do They Protect Against Disease or Enhance it?

Thomas E. Cecere, S. Michelle Todd and Tanya LeRoith *

Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA; E-Mails: tcecer@vt.edu (T.C.); smtodd@vt.edu (S.T.)

* Author to whom correspondence should be addressed; E-Mail: tleroith@vt.edu;
Tel.: +1-540-231-7627; Fax: +1-540-231-6033.

Received: 2 April 2012; in revised form: 3 May 2012 / Accepted: 7 May 2012 / Published: 15 May 2012

Abstract: Regulatory T cells (Tregs) are a subset of T cells that are responsible for maintaining peripheral immune tolerance and homeostasis. The hallmark of Tregs is the expression of the forkhead box P3 (FoxP3) transcription factor. Natural regulatory T cells (nTregs) are a distinct population of T cells that express CD4 and FoxP3. nTregs develop in the thymus and function in maintaining peripheral immune tolerance. Other CD4+, CD4−CD8−, and CD8+CD28− T cells can be induced to acquire regulatory function by antigenic stimulation, depending on the cytokine milieu. Inducible (or adaptive) Tregs frequently express high levels of the interleukin 2 receptor (CD25). Atypical Tregs express FoxP3 and CD4 but have no surface expression of CD25. Type 1 regulatory T cells (Tr1 cells) produce IL-10, while T helper 3 cells (Th3) produce TGF-β. The function of inducible Tregs is presumably to maintain immune homeostasis, especially in the context of chronic inflammation or infection. Induction of Tregs in coronaviral infections protects against the more severe forms of the disease attributable to the host response. However, arteriviruses have exploited these T cell subsets as a means to dampen the immune response allowing for viral persistence. Treg induction or activation in the pathogenesis of disease has been described in both porcine reproductive and respiratory syndrome virus, lactate dehydrogenase elevating virus, and mouse hepatitis virus. This review discusses the development and biology of regulatory T cells in the context of arteriviral and coronaviral infection.
Keywords: regulatory T cell; arterivirus, porcine reproductive and respiratory syndrome virus; lactate dehydrogenase-elevating virus; coronavirus

1. Introduction

Regulatory T cells (Tregs) provide a balance between combating pathogens and the risk of developing autoimmunity or overwhelming inflammation. Regulatory T cells can be divided into two groups—natural Tregs develop in the thymus, while inducible Tregs are generated in the periphery from conventional T cells in response to different stimuli. The natural Tregs are the best characterized of the two groups and make up approximately 5–10% of circulating T lymphocytes in mice and humans [1]. Regulatory T cells are primarily characterized by the expression of the transcription factor FoxP3, although conventional T cells can transiently express FoxP3 under some circumstances [2]. FoxP3 maintains Treg gene expression induced by other transcription factors rather than actually driving T reg development. However, FoxP3 is essential for Treg function since loss of FoxP3 function results in severe lymphoproliferative disease and autoimmunity in humans and mice [3]. The role of FoxP3 in maintaining self-tolerance was first identified in scurfy mice, and then in humans with immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, both of which have a FoxP3 mutation as the underlying genetic defect. Both natural and induced Treg cells (iTregs) have unique surface markers that differentiate them from conventional T cells; however differentiating nTregs from iTregs has been challenging. Additional subsets of iTregs that have been described in humans and mice include Tr1 cells, T helper 3 cells (Th3), and CD8+ Tregs [4]. Tr1 and Th3 cells do not express FoxP3 but were considered “original” Tregs because of their suppressive function [2]. A number of studies have shown that Tregs affect the magnitude of immunity and outcome of viral infections, especially with persistent viruses that give rise to chronic lesions [5]. The ability of viruses to induce proliferation and activation of regulatory T cells likely contributes to delayed clearance and persistence in the host.

Investigators have shown that both coronavirus and arterivirus infection results in an increase in CD4+CD25+FoxP3+ lymphocytes. However, the outcomes of Treg activation for each virus are different. Treg induction by porcine arterivirus suppresses the immune response [6] which may allow for viral persistence, while Treg induction by neurotropic mouse hepatitis virus limits demyelination [7]. In this review we discuss the development of Tregs in the context of coronaviral and arteriviral infection with special emphasis on porcine arterivirus and mouse hepatitis virus.

2. Regulatory T Cell Development

2.1. Natural Tregs

Natural regulatory T cells (nTregs) develop in the thymus through interactions between the high-affinity T cell receptor and cognate antigens on thymic epithelial cells. Co-stimulation through CD28 and common gamma (cγ) chain cytokines, especially IL-2 and IL-7 are necessary for nTreg development. Signal transducer and activation of transcription 5 (STAT5) signaling through the cγ
chain is also required. Thymic development of nT\textsubscript{reg} cells follows a two-step process. First, thymocytes upregulate CD25 and other IL-2 signaling molecules in response to TCR/CD28 co-stimulation and second, CD4\textsuperscript{+}CD25\textsuperscript{high}FoxP3\textsuperscript{-} T\textsubscript{reg}s respond to IL-2 independent of the TCR, and induce FoxP3 expression in response to STAT5 activation [1]. T\textsubscript{reg} cell-intrinsic NF-\kappaB activation is essential for thymic T\textsubscript{reg} development [1]. Naturally occurring T\textsubscript{reg}s cannot produce IL-2 and therefore rely on paracrine IL-2 production from conventional T cells. Mice deficient in IL-2 or CD25 have reduced numbers of FoxP3\textsuperscript{+} T cells and a dramatic reduction in peripheral and thymic T\textsubscript{reg}s. In humans, Hassall’s corpuscles in the thymic medulla secrete thymic stroma lymphopoietin (TSLP) which activates immature dendritic cells and upregulates the expression of co-stimulatory molecules. The activated DCs induce FoxP3 expression in CD4\textsuperscript{+}CD8\textsuperscript{-}CD25\textsuperscript{-} thymocytes [8].

2.2. Inducible T\textsubscript{reg}s

Less well-characterized are the inducible T\textsubscript{reg}s (iT\textsubscript{reg}s) that develop from conventional T cells under certain conditions. iT\textsubscript{reg}s are induced by prolonged exposure to circulating antigen, chronic inflammation, or weak co-stimulation in the periphery [2]. Soluble factors such as the cytokines IL-4, IL-10 and TGF-\beta, retinoic acid or neuropeptides can upregulate FoxP3 expression and generate iT\textsubscript{reg}s in the periphery. Increased expression of FoxP3 results in upregulation of other T\textsubscript{reg} molecules, including CTLA-4, GITR, and CD127. CD4\textsuperscript{+} T cells that express high levels of the IL-2\textalpha receptor (CD25\textsuperscript{high}) do not respond to T cell receptor (TCR) activation or mitogen stimulation, and inhibit IL-2 transcription in CD25\textsuperscript{-} cells. Suppression of CD25\textsuperscript{-} cells is contact dependent, and requires activation of the T\textsubscript{reg}s through the TCR; however, once activated, the suppressor effector function is nonspecific [9]. CD4\textsuperscript{+}CD25\textsuperscript{-} T cells suppress the immune response to some viruses, protozoa, and bacteria, and aid the survival of intracellular pathogens [10] most likely by potent suppression of proliferation and IFN-\gamma production of both CD4\textsuperscript{+} and CD8\textsuperscript{+} T lymphocytes [11]. Tr1 cells secrete high amounts of IL-10 and moderate amounts of TGF-\beta. Inhibiting IL-10 with neutralizing antibody blocks the suppressor effects of Tr1 cells [4]. Th3 cells produce high concentrations of TGF-\beta and moderate amounts of IL-10, and the suppressor effects are not antigen specific [4]. Interestingly, Th3 cells suppress the activation of both Th1 and Th2 cell clones while other subsets primarily inhibit Th1 cells and have no effect on Th2 cells [4]. Other cells with adaptive regulatory function include some CD4\textsuperscript{-}CD8\textsuperscript{-} and CD8\textsuperscript{+}CD28\textsuperscript{-} T cells [8]. Early after iT\textsubscript{reg}s are stimulated, they express high levels of cell-cycle progression and T cell activation-associated genes [12], mimicking genes that are upregulated in activated effector T cells. As iT\textsubscript{reg}s mature, expression of these genes diminishes while they remain high in mature effector T cells. By 10 days after differentiation into iT\textsubscript{reg}s, most cell cycle progression and T cell activation genes are expressed at levels approximately 3 times lower than in effector T cells. In addition, genes in the FoxO family of transcription factors are over-expressed in iT\textsubscript{reg}s compared to overexpression of the FoxM1 family in effector cells [12].

2.3. Viral Mediated-T\textsubscript{reg} Activation

Regulatory T cells typically increase late in chronic viral disease to prevent a persistent inflammatory response and viral-mediated immunopathology. In fact, tissue-protective effects of T\textsubscript{reg} were shown in models of respiratory syncytial virus, Friend virus, and West Nile
Virus infection [13,14]. Additionally, T\textsubscript{reg} responses to viruses (and bacteria) form the basis of the “hygiene hypothesis”. Infection with influenza A in suckling mice protected these mice as adults against allergy induced airway hyperactivity due to the expansion of allergen-specific regulatory T cells [15]. Conversely, T\textsubscript{regs} are widely accepted as a key contributor in modulating the host immune response to viral infection. T\textsubscript{regs} are an important component in regulating the magnitude of the immune response to infection, thus preventing excessive inflammation and tissue damage. But, they can also be inappropriately induced by viruses in order to swing the balance of the immune response in favor of maintaining viral infection [16]. In this way T\textsubscript{regs} contribute to persistent infection of many viruses including Friend virus, herpes simplex virus, hepatitis C virus, hepatitis B virus, human immunodeficiency virus, feline immunodeficiency virus, simian immunodeficiency virus, cytomegalovirus and Epstein-Barr virus [13,14,17-26].

3. Arteriviruses

3.1. Porcine Reproductive and Respiratory Syndrome Virus

Within a susceptible herd, reproductive failure due to PRRSV infection can range from sporadic abortions to abortion storms that may persist within the herd for up to 6 months [27]. Exposure late in gestation may manifest as late-term abortion, or stillborn, partially autolyzed, or mummified fetuses [27]. Neonatal infection results in severe dyspnea and tachypnea, and mortality of up to 100%, while disease in weaned pigs is primarily due to pneumonia and secondary bacterial or viral infections [27]. PRRSV infection is also associated with decreased local cellular immunity, resulting in increased susceptibility to secondary bacterial and viral infections [28-30]. Piglets infected with PRRSV in utero have a decreased innate immune response to bacterial pathogens [28]. In utero infection with PRRSV inhibits macrophage phagocytosis of Salmonella spp., and inhibits alveolar macrophage oxidative burst [28]. Additionally, both PRRSV infection and vaccination decreases the efficiency of vaccines against Mycoplasma hyopneumoniae [31] and porcine pestivirus [32]. Infection and vaccination with PRRSV induces a rapid, non-neutralizing antibody response, and an early, weak, non-specific gamma interferon (IFN-\(\gamma\)) response [33,34]. A PRRSV-specific T lymphocyte IFN-\(\gamma\) response does not appear until at least 2 weeks after infection, [35] gradually increases, and plateaus at 6 months postinfection. This IFN-\(\gamma\) is associated with a slow increase in neutralizing antibody [33,36]. Peak viremia and shedding occur before development of a protective neutralizing antibody and IFN-\(\gamma\) [36]. Acute infection is followed by persistence of lower levels of virus in lymphoid tissue and then clearance after several months [36]. The cause of the delayed IFN-\(\gamma\) and neutralizing antibody response resulting in persistent infection is unknown. The ability to induce a rapid IFN-\(\gamma\) response is important both for viral clearance and heterologous protection by vaccination [37,38]. Vaccine strains currently in use in the United States do not provide adequate heterologous protection, perhaps because of their inability to stimulate an adequate IFN-\(\gamma\) response. We hypothesized that one reason for the inadequate IFN-\(\gamma\) may be due to the ability of PRRSV to stimulate regulatory T cells in vitro [39].

PRRSV infection results in a significant upregulation of IL-10 expression in peripheral blood mononuclear cells and pulmonary alveolar macrophages in vivo and in vitro [40-43]. However, the ability of PRRSV to induce IL-10 appears to vary depending on strain and it was recently
demonstrated that a highly virulent PRRSV strain did not induce IL-10 \textit{in vitro} or \textit{in vivo} [44-46]. The primary action of IL-10 is to inhibit inflammatory cytokines including IL-1β, IL-6, TNF, and IL-12, and antagonize the function of antigen presenting cells by decreased surface expression of MHC class I and II molecules and reduction of costimulatory molecules [47]. Additionally, IL-10 inhibits the production of nitric oxide by macrophages [48,49]. Since IL-12-mediated production of IFN-γ by pulmonary alveolar macrophages reduces PRRS viral titers in the lungs and serum [50], inhibition of IL-12 synthesis by IL-10 likely enhances the occurrence of natural disease. IL-10 also affects innate immunity by inhibiting the response to Toll-like receptors (TLR), including TLR7 and TLR8 that recognize single-stranded viral RNA [51]. IL-10 treated DCs induce the proliferation of regulatory T cells (T_{\text{regs}}) as well as antigen-specific anergy in CD4+ and CD8+ T lymphocytes [47]. IL-10 not only plays a role in the development of type 1 T_{\text{regs}} (Tr1), but is also one of the primary mechanisms by which T_{\text{regs}} inhibit effector T lymphocyte function [51].

In previous experiments, we have shown that PRRSV infection increases the number of CD4+CD25+FoxP3+ regulatory T cells in the lungs and PBMCs of pigs (LeRoith, unpublished). Silva-Campa demonstrated that the CD25+FoxP3+ cells induced by PRRSV produce TGF-β, suggesting that the cells are not only increased, but are also functional [39]. These CD25+FoxP3+ T_{\text{regs}} exhibited suppressor activity \textit{in vitro}. This same group reported that while American genotype PRRSV strains were capable of inducing T_{\text{reg}} and upregulating TGF-β production, DCs infected with European genotype PRRSV induced neither TGF-β nor T_{\text{regs}} [52]. Wongyanin and colleagues demonstrated that peripheral blood mononuclear cells (PBMCs) cultured with American genotype PRRSV \textit{in vitro} induced virus-specific CD4+CD25+FoxP3+ T_{\text{regs}} and the addition of monocyte-derived dendritic cells (MoDC) to the cell culture enhanced T_{\text{reg}} induction [53]. Not only was there a significant increase in the numbers of CD4+CD25+FoxP3+ cells, but these PRRSV-specific T_{\text{regs}} exhibited suppressive activity when co-cultured with PHA-stimulated autologous peripheral leukocytes. The authors reported in this study that PBMCs collected from PRRSV-infected pigs 10 days post-inoculation exhibited significantly higher numbers of CD4+CD25+FoxP3+ lymphocytes when cultured in the presence of PRRSV compared to mock-infected cell lysate or PBMCs alone. The role of PRRSV nucleocapsid protein (N) in T_{\text{reg}} induction was recently described, and it was found that N-protein induced IL-10 producing cells and CD4+CD25+FoxP3+ T_{\text{regs}} in a DC \textit{in vitro} system [54]. In this study, T_{\text{reg}} induction was found to be dependent, at least in part, on IL-10, as neutralization of IL-10 by anti-IL-10 antibody drastically reduced the PRRSV-induced T_{\text{regs}}.

In order to assess the potential benefit of using a mucosal rather than parenteral immunization approach, Dwivedi \textit{et al.} investigated the ability of an intranasally delivered PRRS-modified live vaccine (MLV) augmented with a potent \textit{Mycobacterium tuberculosis} whole cell lysate adjuvant to induce cross protective immunity against a heterologous PRRSV strain. Vaccinated pigs had a reduced frequency of T_{\text{regs}} in respiratory mucosal and systemic sites compared to unvaccinated pigs, and this correlated with decreased secretion of immunosuppressive cytokines IL-10 and TGF-β, diminished lung pathology, and increased PRRSV neutralizing antibody titers and IFN-γ secretion [55,56]. These findings suggest that the route of immunization and adjuvant-mediated immunomodulation may influence T_{\text{reg}} dynamics, thereby facilitating or negating efficient viral clearance. This same group recently reported on pigs that were maintained on a commercial farm and experimentally infected with PRRSV.
At two days post-inoculation, infected pigs had an increased frequency of circulating CD4^+CD25^+Foxp3^+ Tregs, reduced frequency of CD4^+CD8^- and CD4^-CD8^+ T cells, and enhanced IL-10, IL-4 and IL-12 secretion [57].

It is unknown which components of the virus are responsible for Treg proliferation, but this is currently under investigation by our group. We demonstrated that Treg induction by PRRSV results in increased susceptibility to natural *Mycoplasma hyopneumoniae* infection [6]. In this study, pigs were inoculated with a virulent strain of PRRSV and a modified live vaccine derived from the same strain. The attenuated strain contains silent mutations in the replicase region (ORF 1) [58] and conservative or non-conservative amino acid changes in the structural proteins [58]. We hypothesized that even with changes that decrease pathogenicity, the mutations would not alter the virus’s ability to stimulate Tregs. Consistent with our hypothesis, we found that, although attenuated, the vaccine strain did not differ from the parent strain in its ability to activate Tregs. The animals inoculated with the attenuated vaccine did not differ from animals inoculated with the parent strain in the severity of *M. hyopneumoniae*-mediated disease [6]. Similar to previous findings that infection with wild type PRRSV or vaccination with PRRS MLV vaccines has been shown to decrease the efficacy of *M. hyopneumoniae* vaccines [31], inoculation with each of the three PRRS viruses in this study resulted in activation of regulatory T cells and likely decreased the ability of the pigs to mount an effective anti-bacterial immune response.

Vaccine efficacy appears to be related to the ability to stimulate IFN-γ production and efficacy against heterologous virus challenge seems to correlate more with the ability to stimulate IFN-γ than homology of the vaccine strain to the infective strain. Current vaccines fail to protect against other strains [59], which may be due to their inability to stimulate IFN-γ production. Our study was the first to show the correlation between vaccine induction of Tregs and increased susceptibility to bacterial infection. Although Tregs that are induced by PRRS *in vitro* produce TGF-β [39], the induction of Tregs may indirectly result in IL-10 production, a phenomenon that is well established in the PRRS literature [41,42]. Production of IL-10 instead of IFN-γ by the MLV vaccine strain would lead to a lack of heterologous protection, and decreased efficacy of other vaccines, as seen by other authors [31]. Our results suggest that mutations in the vaccine strain that result in attenuation of the virus do not alter the virus’s ability to stimulate Tregs [6]. This information can help us design vaccines in which the Treg-stimulating epitopes are mutated or deleted in order to stimulate a robust virus-specific IFN-γ response, and provide protection against heterologous strains [6].

### 3.2. Lactate Dehydrogenase Elevating Virus

Lactate dehydrogenase-elevating virus (LDV) has been described as an “ideal” persistent virus since it is associated with life-long viral infection in mice in the absence of clinical disease while escaping the host immune response [60,61]. Cytotoxicity is limited to resident tissue macrophages, in which viral replication is maintained. Lifelong immunotolerance is maintained and has been shown to be due in part to continuous generation of LDV antigens in the thymus [62]. In addition, LDV infection and replication within macrophages appears to be robustly resistant to typical antiviral immune responses including interferon-α/β, antiviral antibodies and virus-specific cytotoxic T lymphocytes [60]. Collectively, these features suggest a role for Tregs in the pathogenesis of LDV infection.
Inada and colleagues demonstrated that mice challenged with heat-inactivated or killed LDV induced a strong virus-specific delayed-type hypersensitivity (DTH) reaction, whereas a delayed hypersensitivity reaction was undetectable in young (1–3 month-old) mice challenged with live virus [63]. In these experiments pretreatment with cyclophosphamide partially restored the DTH response, which was attributed to cyclophosphamide mediated elimination of suppressor T cells [64,65]. Live virus also elicited a DTH response in old mice (> 8 months) without cyclophosphamide treatment, which is not surprising in light of the fact that older mice have reduced suppressor T cell activity. The cumulative findings from this study suggest that inoculation with live LDV induces suppressor T cells, and that this dampens the virus-specific delayed hypersensitivity response [63].

Further demonstrating the immunosuppressive ability of LDV, Robertson, et al. reported that co-infection with LDV and Friend virus (FV) delayed the FV specific CD8+ T cell response and that this resulted in an increase in duration and severity of the acute phase of FV infection [66]. The suppressed FV-specific CD8+ T cell response occurred in mice acutely co-infected with LDV and FV as well as in mice inoculated with LDV 8 weeks prior to FV infection. In addition, mice infected with LDV exhibited significant regulatory T cell-mediated suppression of IFN-γ production by FV-specific CD8+ T cells that peaked at day 3 post-infection and was diminished by day 7 post-infection. However, failure of FV/LDV co-infected mice to mount a strong CD8+ T cell response was not attributed solely to Treg-mediated suppression, because neither depletion of CD4+ cells nor pre-treatment with anti-CD25 antibody restored the normal CD8+ response [66].

The antigen presenting ability of spleen, lymph node and peritoneal macrophages from LDV infected mice was shown to be diminished as measured in vitro by reactivation of memory T cells. The experiments showed that LDV-mediated impairment of antigen presentation was not due to diminished uptake of antigen by macrophages and LDV-infected peritoneal macrophages were not immunosuppressive in cell culture. Rather, the authors concluded that the decrease in antigen presenting ability of LDV-infected macrophages was related to reduced expression of Ia antigen or virus-mediated elimination of Ia positive macrophages from the peritoneum [67].

3.3. Coronavirus

Much attention on the interaction of Tregs and viral pathogens has focused on chronic disease, demonstrating the ability of Tregs to delay or prevent viral clearance leading to persistent infection [16,68]. From the host point-of-view, virus-induced Tregs represent a detrimental factor in the context of chronic or persistent infection. However, coronavirus infection in the central nervous system of mice highlights a beneficial role of Tregs in reducing bystander damage as a consequence of acute infection. Coronavirus infection of the central nervous system exemplifies the necessity of a delicately balanced and finely orchestrated immune response. While a rapid and strong pro-inflammatory response aids in viral clearance, host tissue destruction secondary to immunopathology can be a deleterious side effect. An appropriate anti-inflammatory response is necessary for minimizing collateral damage while still allowing clearance of the invading pathogen.

Mice infected with the neurovirulent strain of mouse hepatitis virus JHM (JHMV) develop a rapidly progressive, fatal disease that has been shown to be mediated, in part, by CD4+ T cells. This was evidenced by the fact that infection with a recombinant JHMV strain containing a single mutation in an
immunodominant CD4+ T cell epitope (rJ.M_Y135Q) resulted in nonlethal mild encephalitis, and the decrease in mortality correlated with decreased numbers of virus-specific CD4+ T cells in the brain [69]. Further investigations found that significantly higher levels of the pro-inflammatory cytokines/chemokines IL-6, CCL2, CCL5 and IFN-γ were detected in the brains of mice infected with the non-mutated recombinant JHMV strain (rJ) compared to rJ.M_Y135Q-infected mice [70]. CD4+ Tregs were shown to be critical in ameliorating disease because (1) greater numbers of Tregs were detected in the brains of rJ.M_Y135Q-infected mice compared to rJ-infected mice, (2) their depletion in rJ.M_Y135Q-infected mice increased morbidity and mortality, and (3) adoptive transfer of Tregs into rJ-infected mice increased survival from 0% to 50% [70]. The authors concluded that in the setting of acute encephalitis, Tregs may aid in limiting immunopathology, thus decreasing clinical disease without delaying viral clearance.

In contrast to the neurovirulent JHMV strain, mice infected with an attenuated JHMV variant (J2.2-V-1) develop chronic demyelinating encephalomyelitis and the demyelination is largely due to immunopathology associated with viral clearance [71-73]. Trandem et al. demonstrated that adoptive transfer of Tregs ameliorated clinical disease and demyelination in J2.2-V-1-infected mice and did not delay viral clearance in immunocompetent C57BL/6 mice [74]. The authors provided evidence that this improved clinical outcome was due in part to Tregs functioning in the draining cervical lymph nodes to suppress T cell proliferation, dendritic cell activation and expression of pro-inflammatory mediators. These findings further support the notion that Tregs play an important role in limiting neuropathology associated with mouse hepatitis virus (MHV) infection while still allowing for viral clearance.

Identification and characterization of pathogen-specific epitopes targeted by Tregs has received considerable interest due to possible therapeutic interventions aimed at diminishing inflammation-induced tissue damage in a pathogen-specific fashion. Zhao and colleagues identified Tregs that specifically recognize two mouse hepatitis virus-specific epitopes using the neurotropic rJ2.2 strain of mouse hepatitis virus, which is known to cause mild acute encephalitis and chronic demyelination [7,75]. These virus-specific Tregs were present in the virus-infected central nervous system and, based on concurrent detection with virus-specific effector CD4+ T cells and identification within the naive T cell precursor pools in the spleen and lymph nodes, are presumed to arise from the natural Treg pool. In addition, the virus-specific Tregs expressed IL-10 and IFN-γ upon stimulation with viral peptide and suppressed proliferation of cognate-epitope specific effector CD4+ T cells. While Tregs are known to play a critical role in reducing immunopathology and clinical disease in rJ2.2-infected mice, the results from this study suggest that virus-specific Tregs may be significantly more potent in diminishing immunopathology associated with encephalomyelitis compared to adoptive transfer of natural Tregs, particularly during acute infection when maximum viral antigen is present [7,74,76].

In contrast to the protective effect of Tregs in the pathogenesis of neurotropic mouse hepatitis virus infection, Shalev and colleagues demonstrated that Tregs contributed to more severe fulminating viral hepatitis in susceptible mice infected with murine hepatitis virus strain 3. This phenomenon was mediated in part by increased Treg expression of the immunosuppressive cytokine fibrinogen-like protein 2 [77]. These findings suggest that Treg activation following infection with mouse hepatitis virus may culminate in different outcomes depending on the anatomic location of disease, such that
they are paradoxically beneficial to the host in limiting CNS disease but harmful in potentiating fulminant hepatitis.

4. Conclusions

Regulatory T cells are critical for maintaining immune tolerance and immune homeostasis by protecting against devastating autoimmune disease and overwhelming inflammation. Without these subsets of T cells, animals quickly succumb to inflammatory or autoimmune diseases. Activation of T\textsubscript{regs} is critical in some viral infections, especially neurotropic coronaviral infection, to limit immunopathology. However, some viruses, including arteriviruses, have exploited these cells to enhance their replication in the host and become persistent. The function of T\textsubscript{regs} in coronavirus-infected mice highlights the potential dichotomy in protective versus harmful outcome, depending on the anatomic location of disease. Along this line of reasoning, one might argue that the perspective of T\textsubscript{regs} protecting the host or enhancing disease may depend on which outcome is more deleterious, viral persistence or immunopathology associated with viral clearance.

Understanding the mechanism of T\textsubscript{reg} activation by viruses is critical for identifying new strategies to prevent the immunosuppressive effects or enhance the immunoprotective effects on the host. In many cases, activation of T\textsubscript{regs} not only dampens the immune response to the virus, but non-specifically dampens the immune response to other pathogens. While the initial immune suppression likely plays a role in virus persistence, the non-specific immune suppression is one of the mechanisms by which secondary infection can occur. The complete effects of these viruses on the immune response of the host are still under investigation. The ability of certain viruses to stimulate T\textsubscript{regs} provides valuable insight as to how viruses modulate the immune system. Understanding the mechanisms of T\textsubscript{reg} induction is important in determining the contribution of these viruses to the development of disease and is also essential for vaccine development.

Acknowledgments

This work was supported in part by funding from the National Pork Board and Virginia 229 funds.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Guckel, E.; Frey, S.; Zaiss, M.M.; Schett, G.; Ghosh, S.; Voll, R.E. Cell-intrinsic NF-kappaB activation is critical for the development of natural regulatory T cells in mice. *PLoS One* **2011**, *6*, e20003.

2. Bilate, A.M.; Lafaille, J.J. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. *Annu. Rev. Immunol.* **2012**, *30*, 733–758.

3. Bennett, C.L.; Christie, J.; Ramsdell, F.; Brunkow, M.E.; Ferguson, P.J.; Whitesell, L.; Kelly, T.E.; Saulsbury, F.T.; Chance, P.F.; Ochs, H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nature genetics* **2001**, *27*, 20–21.
4. Beissert, S.; Schwarz, A.; Schwarz, T. Regulatory T cells. *J. Invest Dermatol.* **2006**, *126*, 15–24.
5. Rouse, B.T.; Sarangi, P.P.; Suvas, S. Regulatory T cells in virus infections. *Immunol. Rev.* **2006**, *212*, 272–286.
6. LeRoith, T.; Hammond, S.; Todd, S.M.; Ni, Y.; Cecere, T.; Pelzer, K.D. A modified live PRRSV vaccine and the pathogenic parent strain induce regulatory T cells in pigs naturally infected with *Mycoplasma hyopneumoniae*. *Vet. Immunol. Immunopathol.* **2011**, *140*, 312–316.
7. Zhao, J.; Fett, C.; Trandem, K.; Fleming, E.; Perlman, S. IFN-gamma- and IL-10-expressing virus epitope-specific Foxp3(+) T reg cells in the central nervous system during encephalomyelitis. *J. Exp. Med.* **2011**, *208*, 1571–1577.
8. Sakaguchi, S.; Miyara, M.; Costantino, C.M.; Hafler, D.A. FOXP3+ regulatory T cells in the human immune system. *Nat. Rev. Immunol.* **2010**, *10*, 490–500.
9. Thornton, A.M.; Shevach, E.M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. *J. Immunol.* **2000**, *164*, 183–190.
10. Sakaguchi, S. Regulatory T cells: Mediating compromises between host and parasite. *Nat. Immunol.* **2003**, *4*, 10–11.
11. Bacchetta, R.; Gregori, S.; Roncarolo, M.G. CD4+ regulatory T cells: Mechanisms of induction and effector function. *Autoimmun. Rev.* **2005**, *4*, 491–496.
12. Prots, I.; Skapenko, A.; Lipsky, P.E.; Schulze-Koops, H. Analysis of the transcriptional program of developing induced regulatory T cells. *PLoS One* **2011**, *6*, e16913.
13. Robertson, S.J.; Messer, R.J.; Carmody, A.B.; Hasenkrug, K.J. *In vitro* suppression of CD8+ T cell function by Friend virus-induced regulatory T cells. *J. Immunol.* **2006**, *176*, 3342–3349.
14. Belkaid, Y.; Rouse, B.T. Natural regulatory T cells in infectious disease. *Nat. Immunol.* **2005**, *6*, 353–360.
15. Chang, Y.J.; Kim, H.Y.; Albacker, L.A.; Lee, H.H.; Baumgarth, N.; Akira, S.; Savage, P.B.; Endo, S.; Yamamura, T.; Maaskant, J.; et al. Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. *J. Clin. Invest* **2011**, *121*, 57–69.
16. Belkaid, Y. Regulatory T cells and infection: A dangerous necessity. *Nat. Rev. Immunol.* **2007**, *7*, 875–888.
17. Mexas, A.M.; Fogle, J.E.; Tompkins, W.A.; Tompkins, M.B. CD4+CD25+ regulatory T cells are infected and activated during acute FIV infection. *Vet. Immunol. Immunopathol.* **2008**, *126*, 263–272.
18. Dittmer, U.; He, H.; Messer, R.J.; Schimmer, S.; Olbrich, A.R.; Ohlen, C.; Greenberg, P.D.; Stromnes, I.M.; Iwashiwo, M.; Sakaguchi, S.; et al. Functional impairment of CD8(+) T cells by regulatory T cells during persistent retroviral infection. *Immunity* **2004**, *20*, 293–303.
19. Estes, J.D.; Li, Q.; Reynolds, M.R.; Wietgrefe, S.; Duan, L.; Schacker, T.; Picker, L.J.; Watkins, D.I.; Lifson, J.D.; Reilly, C.; et al. Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. *J. Infect Dis.* **2006**, *193*, 703–712.
20. Pereira, L.E.; Villinger, F.; Onlamoon, N.; Bryan, P.; Cardona, A.; Pattanapanysat, K.; Mori, K.; Hagen, S.; Picker, L.; Ansari, A.A. Simian immunodeficiency virus (SIV) infection influences the level and function of regulatory T cells in SIV-infected rhesus macaques but not SIV-infected sooty mangabeys. *J. Virol.* **2007**, *81*, 4445–4456.
21. Karlsson, I.; Malleret, B.; Brochard, P.; Delache, B.; Calvo, J.; Le Grand, R.; Vaslin, B. FoxP3+ CD25+ CD8+ T-cell induction during primary simian immunodeficiency virus infection in cynomolgus macaques correlates with low CD4+ T-cell activation and high viral load. *J. Virol.* 2007, 81, 13444–13455.

22. Boettler, T.; Spangenberg, H.C.; Neumann-Haefelin, C.; Panther, E.; Urbani, S.; Ferrari, C.; Blum, H.E.; von Weizsacker, F.; Thimme, R. T cells with a CD4+CD25+ regulatory phenotype suppress *in vitro* proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. *J. Virol.* 2005, 79, 7860–7867.

23. Suvas, S.; Kumaraguru, U.; Pack, C.D.; Lee, S.; Rouse, B.T. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. *J. Exp. Med.* 2003, 198, 889–901.

24. Aandahl, E.M.; Michaelsson, J.; Moretto, W.J.; Hecht, F.M.; Nixon, D.F. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. *J. Virol.* 2004, 78, 2454–2459.

25. Marshall, N.A.; Vickers, M.A.; Barker, R.N. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. *J. Immunol.* 2003, 170, 6183–6189.

26. Yang, G.; Liu, A.; Xie, Q.; Guo, T.B.; Wan, B.; Zhou, B.; Zhang, J.Z. Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. *Int Immunol* 2007, 19, 133–140.

27. Rossow, K.D. Porcine reproductive and respiratory syndrome. *Vet. Pathol.* 1998, 35, 1–20.

28. Riber, U.; Nielsen, J.; Lind, P. In utero infection with PRRS virus modulates cellular functions of blood monocytes and alveolar lung macrophages in piglets. *Vet. Immunol. Immunopathol.* 2004, 99, 169–177.

29. Rossow, K.D.; Collins, J.E.; Goyal, S.M.; Nelson, E.A.; Christopher-Hennings, J.; Benfield, D.A. Pathogenesis of porcine reproductive and respiratory syndrome virus infection in gnotobiotic pigs. *Vet. Pathol.* 1995, 32, 361–373.

30. Zeman, D.; Neiger, R.; Yaeger, M.; Nelson, E.; Benfield, D.; Leslie-Steen, P.; Thomson, J.; Miskimins, D.; Daly, R.; Minehart, M. Laboratory investigation of PRRS virus infection in three swine herds. *J. Vet. Diagn. Invest.* 1993, 5, 522–528.

31. Thacker, E.L.; Thacker, B.J.; Young, T.F.; Halbur, P.G. Effect of vaccination on the potentiation of porcine reproductive and respiratory syndrome virus (PRRSV)-induced pneumonia by Mycoplasma hyopneumoniae. *Vaccine* 2000, 18, 1244–1252.

32. Suradhat, S.; Kesdangsakonwut, S.; Sada, W.; Buranapraditkun, S.; Wongsawang, S.; Thanawongnuwech, R. Negative impact of porcine reproductive and respiratory syndrome virus infection on the efficacy of classical swine fever vaccine. *Vaccine* 2006, 24, 2634–2642.

33. Meier, W.A.; Galeota, J.; Osorio, F.A.; Husmann, R.J.; Schnitzlein, W.M.; Zuckermann, F.A. Gradual development of the interferon-gamma response of swine to porcine reproductive and respiratory syndrome virus infection or vaccination. *Virology* 2003, 309, 18–31.

34. Wesley, R.D.; Lager, K.M.; Kehrli, M.E., Jr. Infection with Porcine reproductive and respiratory syndrome virus stimulates an early gamma interferon response in the serum of pigs. *Can. J. Vet. Res.* 2006, 70, 176–182.
35. Xiao, Z.; Batista, L.; Dee, S.; Halbur, P.; Murtaugh, M.P. The level of virus-specific T-cell and macrophage recruitment in porcine reproductive and respiratory syndrome virus infection in pigs is independent of virus load. *J. Virol.* **2004**, *78*, 5923–5933.

36. Lopez, O.J.; Osorio, F.A. Role of neutralizing antibodies in PRRSV protective immunity. *Vet. Immunol. Immunopathol.* **2004**, *102*, 155–163.

37. Diaz, I.; Darwich, L.; Pappaterra, G.; Pujols, J.; Mateu, E. Different European-type vaccines against porcine reproductive and respiratory syndrome virus have different immunological properties and confer different protection to pigs. *Virology* **2006**, *351*, 249–259.

38. Martelli, P.; Gozio, S.; Ferrari, L.; Rosina, S.; De Angelis, E.; Quintavalla, C.; Bottarelli, E.; Borghetti, P. Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity. *Vaccine* **2009**, *27*, 3788–3799.

39. Silva-Campa, E.; Flores-Mendoza, L.; Resendiz, M.; Pinelli-Saavedra, A.; Mata-Haro, V.; Mwangi, W.; Hernandez, J. Induction of T helper 3 regulatory cells by dendritic cells infected with porcine reproductive and respiratory syndrome virus. *Virology* **2009**, *387*, 373–379.

40. Charerntantanakul, W.; Platt, R.; Roth, J.A. Effects of porcine reproductive and respiratory syndrome virus-infected antigen-presenting cells on T cell activation and antiviral cytokine production. *Viral Immunol.* **2006**, *19*, 646–661.

41. Suradhat, S.; Thanawongnuwech, R. Upregulation of interleukin-10 gene expression in the leukocytes of pigs infected with porcine reproductive and respiratory syndrome virus. *J. Gen. Virol.* **2003**, *84*, 2755–2760.

42. Feng, W.H.; Tompkins, M.B.; Xu, J.S.; Zhang, H.X.; McCaw, M.B. Analysis of constitutive cytokine expression by pigs infected in-utero with porcine reproductive and respiratory syndrome virus. *Vet. Immunol. Immunopathol.* **2003**, *94*, 35–45.

43. Gomez-Laguna, J.; Salguero, F.J.; Barranco, I.; Pallares, F.J.; Rodriguez-Gomez, I.M.; Bernabe, A.; Carrasco, L. Cytokine expression by macrophages in the lung of pigs infected with the porcine reproductive and respiratory syndrome virus. *J. Comp. Pathol.* **2010**, *142*, 51–60.

44. Subramaniam, S.; Sur, J.H.; Kwon, B.; Pattnaik, A.K.; Osorio, F.A. A virulent strain of porcine reproductive and respiratory syndrome virus does not up-regulate interleukin-10 levels in vitro or in vivo. *Virus Res.* **2011**, *155*, 415–422.

45. Gimeno, M.; Darwich, L.; Diaz, I.; de la Torre, E.; Pujols, J.; Martin, M.; Inumaru, S.; Cano, E.; Domingo, M.; Montoya, M.; *et al.* Cytokine profiles and phenotype regulation of antigen presenting cells by genotype-I porcine reproductive and respiratory syndrome virus isolates. *Vet. Res.* **2011**, *42*, 9.

46. Darwich, L.; Gimeno, M.; Sibila, M.; Diaz, I.; de la Torre, E.; Dotti, S.; Kuzemtseva, L.; Martin, M.; Pujols, J.; Mateu, E. Genetic and immunobiological diversities of porcine reproductive and respiratory syndrome genotype I strains. *Vet. Microbiol.* **2011**, *150*, 49–62.

47. Enk, A.H. Dendritic cells in tolerance induction. *Immunol. Lett.* **2005**, *99*, 8–11.

48. Fiorentino, D.F.; Zlotnik, A.; Mosmann, T.R.; Howard, M.; O’Garra, A. IL-10 inhibits cytokine production by activated macrophages. *J. Immunol.* **1991**, *147*, 3815–3822.

49. Gazzinelli, R.T.; Oswald, I.P.; James, S.L.; Sher, A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. *J. Immunol.* **1992**, *148*, 1792–1796.
50. Carter, Q.L.; Curiel, R.E. Interleukin-12 (IL-12) ameliorates the effects of porcine respiratory and reproductive syndrome virus (PRRSV) infection. *Vet. Immunol. Immunopathol.* **2005**, *107*, 105–118.

51. Vicari, A.P.; Trinchieri, G. Interleukin-10 in viral diseases and cancer: Exiting the labyrinth? *Immunol. Rev.* **2004**, *202*, 223–236.

52. Silva-Campa, E.; Cordoba, L.; Fraile, L.; Flores-Mendoza, L.; Montoya, M.; Hernandez, J. European genotype of porcine reproductive and respiratory syndrome (PRRSV) infects monocyte-derived dendritic cells but does not induce Treg cells. *Virology* **2010**, *396*, 264–271.

53. Wongyanin, P.; Buranapraditkun, S.; Chokeshai-Usaha, K.; Thanawongnuwech, R.; Suradhat, S. Induction of inducible CD4+CD25+Foxp3+ regulatory T lymphocytes by porcine reproductive and respiratory syndrome virus (PRRSV). *Vet. Immunol. Immunopathol.* **2010**, *133*, 170–182.

54. Wongyanin, P.; Buranapraditkul, S.; Yoo, D.; Thanawongnuwech, R.; Roth, J.A.; Suradhat, S. The role of porcine reproductive and respiratory syndrome virus (PRRSV) nucleocapsid protein for induction of IL-10 and regulatory T lymphocytes (Treg). *J. Gen. Virol.* **2012**.

55. Dwivedi, V.; Manickam, C.; Patterson, R.; Dodson, K.; Murtaugh, M.; Torrelles, J.B.; Schlesinger, L.S.; Renukaradhya, G.J. Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant. *Vaccine* **2011**, *29*, 4058–4066.

56. Dwivedi, V.; Manickam, C.; Patterson, R.; Dodson, K.; Weeman, M.; Renukaradhya, G.J. Intranasal delivery of whole cell lysate of Mycobacterium tuberculosis induces protective immune responses to a modified live porcine reproductive and respiratory syndrome virus vaccine in pigs. *Vaccine* **2011**, *29*, 4067–4076.

57. Dwivedi, V.; Manickam, C.; Binjawadagi, B.; Linhares, D.; Murtaugh, M.P.; Renukaradhya, G.J. Evaluation of immune responses to porcine reproductive and respiratory syndrome virus in pigs during early stage of infection under farm conditions. *Virol. J.* **2012**, *9*, 45.

58. Yuan, S.; Mickelson, D.; Murtaugh, M.P.; Faaberg, K.S. Complete genome comparison of porcine reproductive and respiratory syndrome virus parental and attenuated strains. *Virus Res.* **2001**, *79*, 189–200.

59. Mateu, E.; Diaz, I. The challenge of PRRS immunology. *Vet. J.* **2008**, *177*, 345–351.

60. Plagemann, P.G.; Rowland, R.R.; Even, C.; Faaberg, K.S. Lactate dehydrogenase-elevating virus: An ideal persistent virus? *Springer Semin. Immunopathol.* **1995**, *17*, 167–186.

61. Rowson, K.E.; Mahy, B.W. Lactate dehydrogenase-elevating virus. *J. Gen. Virol.* **1985**, *66*, 2297–2312.

62. Rowland, R.R.; Even, C.; Anderson, G.W.; Chen, Z.; Hu, B.; Plagemann, P.G. Neonatal infection of mice with lactate dehydrogenase-elevating virus results in suppression of humoral antiviral immune response but does not alter the course of viraemia or the polyclonal activation of B cells and immune complex formation. *J Gen Virol* **1994**, *75*, 1071–1081.

63. Inada, T.; Mims, C.A. Live lactate dehydrogenase-elevating virus (LDV) induces suppressor T cells that inhibit the development of delayed hypersensitivity to LDV. *J. Gen. Virol.* **1986**, *67*, 2103–2112.
64. Askenase, P.W.; Hayden, B.J.; Gershon, R.K. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. *J. Exp. Med.* **1975**, *141*, 697–702.

65. Mitsuoka, A.; Baba, M.; Morikawa, S. Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice. *Nature* **1976**, *262*, 77–78.

66. Robertson, S.J.; Ammann, C.G.; Messer, R.J.; Carmody, A.B.; Myers, L.; Dittmer, U.; Nair, S.; Gerlach, N.; Evans, L.H.; Cafruny, W.A.; *et al*. Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. *J. Virol.* **2008**, *82*, 408–418.

67. Isakov, N.; Feldman, M.; Segal, S. Acute infection of mice with lactic dehydrogenase virus (LDV) impairs the antigen-presenting capacity of their macrophages. *Cell Immunol.* **1982**, *66*, 317–332.

68. Li, S.; Gowans, E.J.; Chougnet, C.; Plebanski, M.; Dittmer, U. Natural regulatory T cells and persistent viral infection. *J. Virol.* **2008**, *82*, 21–30.

69. Anghelina, D.; Pewe, L.; Perlman, S. Pathogenic role for virus-specific CD4 T cells in mice with coronavirus-induced acute encephalitis. *Am J Pathol* **2006**, *169*, 209–222.

70. Anghelina, D.; Zhao, J.; Trandem, K.; Perlman, S. Role of regulatory T cells in coronavirus-induced acute encephalitis. *Virology* **2009**, *385*, 358–367.

71. Bergmann, C.C.; Parra, B.; Hinton, D.R.; Ramakrishna, C.; Dowdell, K.C.; Stohlman, S.A. Perforin and gamma interferon-mediated control of coronavirus central nervous system infection by CD8 T cells in the absence of CD4 T cells. *J. Virol.* **2004**, *78*, 1739–1750.

72. Wang, F.I.; Stohlman, S.A.; Fleming, J.O. Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated. *J. Neuroimmunol.* **1990**, *30*, 31–41.

73. Wu, G.F.; Dandekar, A.A.; Pewe, L.; Perlman, S. CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination. *J. Immunol.* **2000**, *165*, 2278–2286.

74. Trandem, K.; Anghelina, D.; Zhao, J.; Perlman, S. Regulatory T cells inhibit T cell proliferation and decrease demyelination in mice chronically infected with a coronavirus. *J. Immunol.* **2010**, *184*, 4391–4400.

75. Fleming, J.O.; Trousdale, M.D.; el-Zaatari, F.A.; Stohlman, S.A.; Weiner, L.P. Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies. *J. Virol.* **1986**, *58*, 869–875.

76. Bergmann, C.C.; Lane, T.E.; Stohlman, S.A. Coronavirus infection of the central nervous system: Host-virus stand-off. *Nat. Rev. Microbiol.* **2006**, *4*, 121–132.

77. Shalev, I.; Wong, K.M.; Foerster, K.; Zhu, Y.; Chan, C.; Maknojia, A.; Zhang, J.; Ma, X.Z.; Yang, X.C.; Gao, J.F.; *et al*. The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis. *Hepatology* **2009**, *49*, 387–397.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).